
Opinion|Videos|September 30, 2025
Understanding the Clinical Needs and Real-World Data in BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
An expert discusses how BCG-unresponsive NMIBC patients have heterogeneous clinical needs requiring individualized treatment strategies, while P&T committees evaluate new therapies by assessing unmet needs and comparing real-world evidence across single-arm trials.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends
4
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
5



























